

ACTH



Adrenocorticotrophic hormone, corticotropin

REF		SYSTEM
03255751 190	100	Elecsys 2010 MODULAR ANALYTICS E170 cobas e 411 cobas e 601 cobas e 602

English

Intended use

Immunoassay for the in vitro quantitative determination of adrenocorticotrophic hormone (ACTH) in human EDTA plasma. The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Summary

Adrenocorticotrophic hormone (ACTH) or corticotropin is a peptide hormone consisting of 39 amino acids. It is produced in the anterior pituitary of the brain as part of the precursor molecule pro-opiomelanocortin (POMC). Tissue-specific cleavage results in ACTH and a range of related peptides.^{1,2} ACTH stimulates formation and secretion of glucocorticoids (especially cortisol) by the adrenal cortex.

The glucocorticoid production is regulated by various factors.^{3,4,5,6} After stimulation (e.g. by physical effort or by the internal body clock), the hypothalamus secretes CRH (corticotropin releasing hormone). CRH acts on the pituitary, which in turn synthesizes and secretes ACTH. Finally, ACTH stimulates secretion of the glucocorticoids by the adrenals. High concentrations of glucocorticoids in the blood inhibit secretion of CRH and ACTH via a negative feedback mechanism.

ACTH concentrations show a diurnal variation with high levels in the morning and low levels in the evening. Therefore, as with cortisol, it is important to know the collection time of the plasma sample for interpretation of the results.

Plasma ACTH measurements are useful in the differential diagnosis of pituitary Cushing's disease (ACTH hypersecretion), autonomous ACTH producing pituitary tumors (e.g. Nelson's syndrome), hypopituitarism with ACTH deficiency and ectopic ACTH syndrome.^{7,8} In addition to cortisol measurements, ACTH determinations can be used together with functional or stimulation tests to diagnose the origin of glucocorticoid overproduction. Similarly, ACTH measurements can be employed to facilitate differential diagnosis of adrenocortical insufficiency (Addison's disease).

ACTH not produced by the pituitary gland is known as ectopic ACTH;⁹ this is often associated with small cell carcinoma of the lung. In rare cases ectopic ACTH can be caused by thymic tumors, pancreatic adenocarcinomas, or bronchial carcinoids. These tumors often secrete ACTH precursors (POMC and pro-ACTH).

The Elecsys ACTH assay employs two monoclonal antibodies specific for ACTH (9-12) and for the C-terminal region (ACTH 36-39).

Due to common antigenic structure, the antibodies recognize intact biologically active ACTH 1-39 and the ACTH precursors POMC and pro-ACTH.²

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 50 µL of sample, a biotinylated monoclonal ACTH-specific antibody, and a monoclonal ACTH-specific antibody labeled with a ruthenium complex^{a)} react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack is labeled as ACTH.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-ACTH-Ab~biotin (gray cap), 1 bottle, 8 mL: Biotinylated monoclonal anti-ACTH antibody (mouse) 0.3 mg/L; MES^{b)} buffer 50 mmol/L, pH 6.2; preservative.
- R2 Anti-ACTH-Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 8 mL: Monoclonal anti-ACTH antibody (mouse) labeled with ruthenium complex 0.3 mg/L; MES buffer 50 mmol/L, pH 6.2; preservative.

b) MES = 2-morpholino-ethane sulfonic acid

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	4 weeks

Specimen collection and preparation

Only the specimens listed below were tested in a sufficient number and found acceptable.

K₂- and K₃-EDTA plasma, collected using siliconized glass tubes or plastic tubes as ACTH adsorbs to non-siliconized glass tubes and thereby reduces sample ACTH values.² Do not use other types of plasma samples.



ACTH



Adrenocorticotrophic hormone, corticotropin

There is no high-dose hook effect at ACTH concentrations up to 1x10⁶ pg/mL.

In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found.

However, under ACTH 1-24 medication, ACTH measurement is not recommended, due to negative interference with the sandwich assay.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

1.00-2000 pg/mL or 0.220-440 pmol/L (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 1.00 pg/mL or < 0.220 pmol/L. Values above the measuring range are reported as > 2000 pg/mL or > 440 pmol/L.

Lower limits of measurement

Lower detection limit of the test

Lower detection limit: 1.00 pg/mL or 0.220 pmol/L

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

Dilution

Not necessary due to the broad measuring range.

Expected values

Studies with the Elecsys ACTH assay using plasma samples from 354 apparently healthy adults gave the following results (5th-95th percentile): 7.2-63.3 pg/mL (1.6-13.9 pmol/L)

The plasma samples were drawn between 7-10 a.m.

ACTH concentrations vary considerably depending on physiological conditions. Therefore, ACTH results should always be evaluated together with simultaneously measured cortisol concentrations.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents and pooled human plasma in a modified protocol (EP5-A) of the CLSI (Clinical and Laboratory Standards Institute): 6 times daily for 10 days (n = 60); repeatability on MODULAR ANALYTICS E170 analyzer, n = 21. The following results were obtained:

Elecsys 2010 and cobas e 411 analyzers								
Sample	Repeatability					Intermediate precision		
	Mean		SD		CV	SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%	pg/mL	pmol/L	%
HP ^{c)} 1	4.9	1.08	0.14	0.031	2.9	0.27	0.059	5.4
HP 2	74.2	16.3	1.45	0.319	2.0	1.75	0.385	2.4
HP 3	1390	306	29.8	6.56	2.1	36.2	7.97	2.6

c) HP = human plasma

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Repeatability				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%
HP 1	4.9	1.08	0.13	0.03	2.7
HP 2	64.3	14.2	0.41	0.09	0.6
HP 3	1205	265	7.83	1.72	0.7

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Intermediate precision				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%
HP 1	4.96	1.09	0.266	0.059	5.4
HP 2	76.1	16.8	2.67	0.588	3.5
HP 3	1444	318	53.6	11.8	3.7

Precision was determined using Elecsys reagents and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplication each for 21 days (n = 84). The following results were obtained:

Elecsys 2010 and cobas e 411 analyzers							
Sample	Repeatability					Intermediate precision	
	Mean		SD		CV	SD	
	pg/mL	pmol/L	pg/mL	pmol/L	%	pg/mL	pmol/L
PC MM ^{d)} 1	51.7	11.4	0.517	0.114	1.0	1.12	0.247
PC MM2	1070	236	11.6	2.55	1.1	25.3	5.57

d) PC MM = PreciControl Multimarker

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers								
Sample	Repeatability					Intermediate precision		
	Mean		SD		CV	SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%	pg/mL	pmol/L	%
PC MM1	52.5	11.6	1.91	0.421	3.6	2.70	0.595	
PC MM2	1170	258	28.4	6.25	2.4	49.4	10.9	

Method comparison

A comparison of the Elecsys ACTH assay (y) with a commercially available ACTH test (x) using clinical samples gave the following correlations (pg/mL):

Number of samples measured: 180

Passing/Bablok ¹¹	Linear regression
$y = 1.08x + 1.23$	$y = 0.90x + 8.17$
$\tau = 0.898$	$r = 0.992$

The sample concentrations were between 5.0 and 941 pg/mL or 1.1 and 207 pmol/L.

Specificity/cross-reactivity

The Elecsys ACTH two-site immunoassay measures intact ACTH 1-39.

When ACTH fragments or peptides were added to a patient's plasma sample with defined ACTH concentration, no interference was observed with ACTH 1-10, ACTH 11-24, beta-MSH, and beta-Endorphin.

ACTH fragments (ACTH 1-17, ACTH 1-24, ACTH CLIP 18-39, ACTH 22-39, alpha-MSH 1-13) can bind to one of the antibodies and thereby negatively



ACTH

Adrenocorticotrophic hormone, corticotropin



interfere with the sandwich formation and lead to lower ACTH values as shown in the following table:

Cross reactant	Concentration of cross reactant pg/mL	Apparent ACTH pg/mL	Change in ACTH concentration pg/mL	Cross-reactivity %
None; reference	0	44.1	not applicable	not applicable
ACTH 1-17	50000	10.6	-33.5	-0.07
	5000	36.9	-7.2	-0.14
	500	42.6	-1.5	-0.31
ACTH 1-24	50000	10.2	-33.9	-0.07
	5000	37.9	-6.2	-0.12
	500	42.5	-1.6	-0.32
ACTH 18-39	50000	2.0	-42.1	-0.08
	5000	14.9	-29.2	-0.58
	500	37.0	-7.1	-1.42
ACTH 22-39	50000	0.00	-44.1	-0.09
	5000	6.3	-37.8	-0.76
	500	29.4	-14.7	-2.94
alpha-MSH	50000	12.3	-31.8	-0.06
	5000	34.3	-9.8	-0.20
	500	41.3	-2.8	-0.56

Under ACTH 1-24 medication, ACTH measurement is not recommended. POMC (partially purified from an adenoma cell line) showed an approx. 1.6 % cross-reactivity at 1560 pmol/L which is approx. 40 times the physiological concentration of ACTH precursors in circulation.²

References

- 1 Cone RD. Anatomy and regulation of the central melanocortin system. *Nature Neurosci* 2005;8:571-578.
- 2 Talbot JA, Kane JW, White A. Analytical and clinical aspects of adrenocorticotrophin determination. *Ann Clin Biochem* 2003;40:453-471.
- 3 Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. *Endocrinol Metab Clin North Am* 2005;34:271-292.
- 4 Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. *Endocrinol Metab Clin North Am* 2005;34:293-313.
- 5 Lin L, Achermann JC. The Adrenal. *Horm Res* 2004;62:22-29.
- 6 Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. *Front Neuroendocrinol* 2004;25:132-149.
- 7 Beauregard C, Dickstein G, Lacroix A. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy. *Treat Endocrinol* 2002;1:79-94.
- 8 Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing's syndrome. *Endocrinol Metab Clin North Am* 2005;34:403-421.
- 9 Oliver RL, Davis JR, White A. Characterization of ACTH related peptides in ectopic Cushing's syndrome. *Pituitary* 2003;6:119-126.
- 10 Wu AHB. *Tietz Clinical Guide To Laboratory Tests*, 4th Edition, WB Saunders Co, 2006: 56 pp.

- 11 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS E, ELECSYS, MODULAR and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2013, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336

